XXXX and Risk of Cardiovascular Events: A Meta-Analysis.

@entity1 @entity64 @entity583 @entity171 @entity170 @entity5520 @entity4381 @entity955 @entity731 @entity65
BACKGROUND AND OBJECTIVES: Some evidence suggests that @entity171 may reduce @entity731 , while concerns have been raised about @entity955 . We conducted a meta-analysis to determine the effects of @entity171 on total adverse cardiovascular (CV) events, @entity955 , @entity583 ( @entity583 ), @entity64 , and @entity65 in adults with or at risk for low bone mass. METHODS: A systematic search of MEDLINE and EMBASE through July 2014 identified 58 randomized controlled trials with longer than 6 months in duration that reported CV events. Absolute risks and the Mantel-Haenszel fixed-effects odds ratios (ORs) and 95% confidence intervals (CIs) of total CV events, @entity955 , @entity583 , @entity64 , and @entity65 were estimated. Subgroup analyses by follow-up duration, population characteristics, @entity5520 types, and route were performed. RESULTS: Absolute risks over 25-36 months in @entity5520 -treated versus control @entity1 were 6.5% versus 6.2% for total CV events; 1.4% versus 1.5% for @entity955 ; 1.0% versus 1.2% for @entity583 ; 1.6% versus 1.9% for @entity64 ; and 1.5% versus 1.4% for @entity65 . @entity5520 treatment up to 36 months did not have any significant effects on total CV events (14 trials; ORs [95% CI]: 0.98 [0.84-1.14]; I2 = 0.0%), @entity955 (41 trials; 1.08 [0.92-1.25]; I2 = 0.0%), @entity583 (10 trials; 0.96 [0.69-1.34]; I2 = 0.0%), @entity64 (10 trials; 0.99 [0.82-1.19]; I2 = 5.8%), and @entity65 (14 trials; 0.88 [0.72-1.07]; I2 = 0.0%) with little between-study heterogeneity. The risk of @entity955 appears to be modestly elevated for @entity4381 (6 trials; 1.24 [0.96-1.61]; I2 = 0.0%), not for oral @entity171 (26 trials; 1.02 [0.83-1.24]; I2 = 0.0%). The CV effects did not vary by subgroups or study quality. CONCLUSIONS: @entity171 do not have beneficial or harmful effects on atherosclerotic CV events, but @entity4381 may modestly increase the risk of @entity955 . Given the large reduction in fractures with @entity171 , changes in @entity170 treatment decision due to CV risk are not justified.
